Search results for "leukemia"

showing 10 items of 976 documents

Role of exosomes released by Chronic Myelogenous Leukemia in the modulation of tumor microenvironment

2012

Myelogenous LeukemiaSettore MED/04 - Patologia Generaletumor
researchProduct

Antiproliferative Effects of St. John’s Wort, Its Derivatives, and Other Hypericum Species in Hematologic Malignancies

2021

Hypericumis a widely present plant, and extracts of its leaves, flowers, and aerial elements have been employed for many years as therapeutic cures for depression, skin wounds, and respiratory and inflammatory disorders. Hypericum also displays an ample variety of other biological actions, such as hypotensive, analgesic, anti-infective, anti-oxidant, and spasmolytic abilities. However, recent investigations highlighted that this species could be advantageous for the cure of other pathological situations, such as trigeminal neuralgia, as well as in the treatment of cancer. This review focuses on the in vitro and in vivo antitumor effects of St. John’s Wort (Hypericum perforatum), its derivat…

MyeloidAngiogenesisDrug Evaluation PreclinicalReviewPharmacologylcsh:Chemistrychemistry.chemical_compoundhyperforinDrug InteractionsMyeloid CellsLymphocyteslcsh:QH301-705.5SpectroscopybiologyapoptosisleukemiaHypericum perforatumGeneral MedicineComputer Science ApplicationsHypericinLeukemiamedicine.anatomical_structurephotodynamic therapyHematologic NeoplasmsHypericumHypericumSt. John’s wortlymphomaCatalysisInorganic ChemistryStructure-Activity Relationshipmultidrug resistanceIn vivoCell Line TumormedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyCell ProliferationPlant Extractsbusiness.industryOrganic Chemistry<i>Hypericum</i>biology.organism_classificationmedicine.diseaseAntineoplastic Agents PhytogenicApoptosis; Hyperforin; Hypericin; Hypericum; Leukemia; Lymphoma; Mul-tidrug resistance; Photodynamic therapy; St. John’s wort; Animals; Antineoplastic Agents Phytogenic; Apoptosis; Cell Line Tumor; Cell Proliferation; Drug Evaluation Preclinical; Drug Interactions; Drug Resistance Neoplasm; Hematologic Neoplasms; Humans; Hypericum; Lymphocytes; Myeloid Cells; Plant Extracts; Structure-Activity RelationshipHyperforinchemistrylcsh:Biology (General)lcsh:QD1-999Drug Resistance NeoplasmhypericinbusinessInternational Journal of Molecular Sciences
researchProduct

The suppressive effects of recombinant human tumor necrosis factor‐alpha on normal and malignant myelopoiesis: Synergism with interferon‐gamma

1988

The modulation of growth of normal and leukemic myeloid progenitor cells in soft agar cultures by recombinant human tumor necrosis factor-alpha (TNF alpha) and recombinant human interferon-gamma (IFN gamma) was investigated. TNF alpha inhibited colony formation of all colony types representing different maturational stages of normal progenitor cells committed to the myeloid lineage with different orders of sensitivity. Blast-type colonies derived from patients with acute myelogenous leukemia were more sensitive to TNF alpha inhibition than progenitor cells purified from normal bone marrow or bone marrow from patients with stable-phase chronic myelogenous leukemia. The response of most colon…

MyeloidBone Marrow CellsBiologyInterferon-gammaBone MarrowmedicineHumansInterferon gammaProgenitor cellTumor Necrosis Factor-alphaAntibodies MonoclonalDrug SynergismCell BiologyHematopoietic Stem Cellsmedicine.diseaseRecombinant ProteinsLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureLeukemia MyeloidImmunologyCancer researchTumor necrosis factor alphaBone marrowMyelopoiesisChronic myelogenous leukemiamedicine.drugThe International Journal of Cell Cloning
researchProduct

Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors

1998

Cell cycle control of both immature and differentiated primary myeloid normal and chronic-phase chronic myeloid leukaemia (CML) cells to growth factor deprivation was studied. CD34+ cells were cultured in liquid culture. After removal of growth factors for 48 h normal cells were very efficiently arrested with the fraction of cells in S phase reduced by 70.8 +/- 6.5% in CD34+ and 50.5 +/- 4.2% in CD34- cells. In contrast, a significantly higher proportion of leukaemic cells remained in S phase. The fraction of S-phase cells was reduced by only 29.3 +/- 5.7% in CD34+ CML cells and 21.2 +/- 3.8% in CD34- cells. This abnormal negative cell cycle control in leukaemic cells was specific for growt…

MyeloidCell growthGrowth factormedicine.medical_treatmentCD34HematologyBiologyCell cyclemedicine.diseaseLeukemiamedicine.anatomical_structureImatinib mesylateCytokinehemic and lymphatic diseasesmedicineCancer researchBritish Journal of Haematology
researchProduct

Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.

2009

Chromosome 1 is the largest human chromosome and contains over 1600 known genes and 1000 novel coding sequences or transcripts. It is, therefore, not surprising that recurrent chromosome 1 abnormalities are regularly encountered in both neoplastic and non-neoplastic medical conditions. The current review is focused on myeloid malignancies where we summarize the relevant published literature and discuss specific karyotype-phenotype associations. We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Specific abnormalities include duplicat…

MyeloidChromosomal translocationBiologyTranslocation GeneticSettore MED/15 - Malattie Del Sanguehemic and lymphatic diseasesmedicineHumansGenes Tumor SuppressorMyelofibrosisGeneticsChromosome AberrationsMyeloproliferative DisordersEssential thrombocythemiaMyelodysplastic syndromesMyeloid leukemiaKaryotypeHematologyGeneral MedicineOncogenesmedicine.diseasemedicine.anatomical_structurePhenotypeChromosomes Human Pair 1Leukemia MyeloidKaryotypingMyelodysplastic Syndromeschomosome 1 myeloid malignancyChromosome DeletionLiterature surveyEuropean journal of haematology
researchProduct

Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-k…

2006

The stem cell leukemia gene SCL, also known as TAL-1, encodes a basic helix-loop-helix transcription factor expressed in erythroid, myeloid, megakaryocytic, and hematopoietic stem cells. To be able to make use of the unique tissue-restricted and spatio-temporal expression pattern of the SCL gene, we have generated a knock-in mouse line containing the tTA-2S tetracycline transactivator under the control of SCL regulatory elements. Analysis of this mouse using different tetracycline-dependent reporter strains demonstrated that switchable transgene expression was restricted to erythrocytes, megakaryocytes, granulocytes, and, importantly, to the c-kit-expressing and lineage-negative cell fracti…

MyeloidErythrocytesGenotypeTransgeneImmunologyMice TransgenicBiologyBiochemistryMiceMegakaryocyteGenes Reporterhemic and lymphatic diseasesProto-Oncogene ProteinsmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsT-Cell Acute Lymphocytic Leukemia Protein 1DNA PrimersRegulation of gene expressionReporter geneBase SequenceCell BiologyHematologyTetracyclineFlow CytometryMolecular biologyRecombinant ProteinsHematopoiesisHaematopoiesisProto-Oncogene Proteins c-kitmedicine.anatomical_structureGene Expression RegulationBone marrowStem cellMegakaryocytesGranulocytesBlood
researchProduct

Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naïve T cells, and favors expansion of regulatory T ce…

2007

AbstractRetroviruses have developed immunmodulatory mechanisms to avoid being attacked by the immune system. The mechanisms of this retrovirus-associated immune suppression are far from clarified. Dendritic cells (DCs) have been attributed a decisive role in these pathogenic processes. We have used the Friend retrovirus (FV) mouse model in order to acquire further knowledge about the role of infection of DCs in virus-induced immunosuppression. About 20% of the myeloid DCs that were generated from the bone marrow of FV-infected mice carried FV proteins. The infection was productive, and infected DCs transmitted the virus in cell culture and in vivo. FV infection of DCs led to a defect in DC …

MyeloidImmunologyPopulationMedizinBone Marrow CellsMice Transgenicchemical and pharmacologic phenomenaCell CommunicationBiologyLymphocyte ActivationT-Lymphocytes RegulatoryBiochemistryMiceImmune systemAntigenImmune TolerancemedicineAnimalsCytotoxic T cellMyeloid CellseducationCell ProliferationAntigen PresentationMice Inbred BALB Ceducation.field_of_studyFollicular dendritic cellsModels ImmunologicalFOXP3hemic and immune systemsDendritic CellsCell BiologyHematologyFriend murine leukemia virusCell biologymedicine.anatomical_structureImmunologyBone marrowRetroviridae InfectionsBlood
researchProduct

Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma

2013

Abstract Altered expression of matricellular proteins can become pathogenic in the presence of persistent perturbations in tissue homeostasis. Here, we show that autoimmunity associated with Fas mutation was exacerbated and transitioned to lymphomagenesis in the absence of SPARC (secreted protein acidic rich in cysteine). The absence of SPARC resulted in defective collagen assembly, with uneven compartmentalization of lymphoid and myeloid populations within secondary lymphoid organs (SLO), and faulty delivery of inhibitory signals from the extracellular matrix. These conditions promoted aberrant interactions between neutrophil extracellular traps and CD5+ B cells, which underwent malignant …

MyeloidLymphoid Tissue: immunologyLymphomaNeutrophilsChronic lymphocytic leukemiaAutoimmunityOsteonectin: geneticsCHRONIC LYMPHOCYTIC-LEUKEMIA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INHIBITORY RECEPTOR LAIR-1; KAPPA-B ACTIVATION; MARGINAL ZONE; INFLAMMATORY DISORDERS; MATRICELLULAR PROTEIN; SPARCMalignant transformationExtracellular matrixKAPPA-B ACTIVATIONLymphoma: immunologyMicehemic and lymphatic diseasesOsteonectinSYSTEMIC-LUPUS-ERYTHEMATOSUSNF-kappa B: immunologyCells CulturedTissue homeostasisB-LymphocytesCulturedNF-kappa BLymphoid Tissue: cytologyCell biologyCD5: immunologyExtracellular MatrixMutant Strainsmedicine.anatomical_structureINHIBITORY RECEPTOR LAIR-1OncologyCD95Stromal cellLymphoid TissueCellsBiologyCD95: geneticsCD5 AntigensINFLAMMATORY DISORDERSExtracellular Matrix: immunologymedicineAnimalsHumansfas ReceptorAntigensB-Lymphocytes: immunologyMATRICELLULAR PROTEINCHRONIC LYMPHOCYTIC-LEUKEMIASPARCLymphoma: geneticsNeutrophil extracellular trapsmedicine.diseaseAnimals; Antigens; Autoimmunity; B-Lymphocytes; B-Lymphocytes: immunology; CD5; CD5: immunology; CD95; CD95: genetics; Cells; Cultured; Extracellular Matrix; Extracellular Matrix: immunology; Humans; Lymphoid Tissue; Lymphoid Tissue: cytology; Lymphoid Tissue: immunology; Lymphoma; Lymphoma: genetics; Lymphoma: immunology; Mice; Mutant Strains; NF-kappa B; NF-kappa B: immunology; Neutrophils; Neutrophils: immunology; Osteonectin; Osteonectin: genetics; Osteonectin: immunologyMice Mutant StrainsCD5Neutrophils: immunologyOsteonectin: immunologyMARGINAL ZONELymphoma SPARC autoimmunityCD5
researchProduct

Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy

2016

Background The association of childhood leukemia with traffic pollution was considered in a number of studies from 1989 onwards, with results not entirely consistent and little information regarding subtypes. Aim of the study We used the data of the Italian SETIL case-control on childhood leukemia to explore the risk by leukemia subtypes associated to exposure to vehicular traffic. Methods We included in the analyses 648 cases of childhood leukemia (565 Acute lymphoblastic–ALL and 80 Acute non lymphoblastic-AnLL) and 980 controls. Information on traffic exposure was collected from questionnaire interviews and from the geocoding of house addresses, for all periods of life of the children. Re…

MyeloidMaleFuture studies010501 environmental sciencesSettore MED/42 - Igiene Generale E Applicata01 natural sciences0302 clinical medicineEconomicahemic and lymphatic diseasesMedicine030212 general & internal medicineChildRoad trafficacute non lymphoblastic leukemia; childhood; environment; leukemia; road traffic; air pollution; case-control studies; child; child preschool; female; humans; infant; Italy; leukemia myeloid acute; male; precursor cell lymphoblastic leukemia-lymphoma; risk; motor vehicles; medicine (all)LeukemiaTraffic pollutionMedicine (all)General MedicinePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemiaMotor VehiclesLeukemia Myeloid AcuteItalyAcute non Lymphoblastic LeukemiaSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICARoad TrafficChild PreschoolFemaleMedical emergencyCase-Control StudieHumanRiskChildhood leukemiaSocio-culturaleAcuteEnvironmentPrecursor Cell Lymphoblastic Leukemia Lymphoma03 medical and health sciencesEnvironmental healthAir PollutionHumansPreschool0105 earth and related environmental sciencesbusiness.industryCase-control studyType specificAmbientaleInfantmedicine.diseaseChildhoodCase-Control StudiesMotor Vehiclebusiness
researchProduct

Intravenous Busulfan for Autologous Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: a Survey of 952 Patients on Behalf of th…

2014

Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67 +/- 2%, 53 +/- 2%, and 40 +/- 2%, respectively. The non-relapse mortality rate at 2 years was 7 +/- 1%. Five patients died from ve…

MyeloidMale[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyBone Marrow Transplantation/mortalitymedicine.medical_treatmentLeukemia Myeloid Acute/therapyHematopoietic stem cell transplantationAntineoplastic Agents Alkylating/administration & dosageLeukemia Myeloid Acute/mortalityGastroenterologyHSAC ONCAutologous stem-cell transplantationHematopoietic Stem Cell Transplantation/mortalityInfusions IntravenousBone Marrow TransplantationAcute leukemiaSurvival Rate/trendsTransplantation Autologous/mortalityLeukemiaData CollectionHematopoietic Stem Cell Transplantation[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedAlkylating3. Good healthEuropeSurvival RateLeukemia Myeloid AcuteLeukemiaFemaleIntravenousAutologousmedicine.drugAdultBusulfan/administration & dosageInfusionsmedicine.medical_specialtyAdolescentCyclophosphamideAntineoplastic AgentsAcuteTransplantation AutologousEurope/epidemiologyData Collection/methodsYoung AdultInternal medicinemedicineHumansAntineoplastic Agents AlkylatingBusulfanSurvival rateAgedRetrospective StudiesTransplantationbusiness.industrySettore MED/15medicine.diseaseTransplantationAdolescent; Adult; Aged; Antineoplastic Agents Alkylating; Bone Marrow Transplantation; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions Intravenous; Leukemia Myeloid Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Autologous; Young Adult; Data CollectionImmunologybusinessBusulfan
researchProduct